Genetic Variation in the β2-Adrenocepter Gene Is Associated with Susceptibility to Bacterial Meningitis in Adults by Adriani, Kirsten S. et al.
Genetic Variation in the b2-Adrenocepter Gene Is
Associated with Susceptibility to Bacterial Meningitis in
Adults
Kirsten S. Adriani
1, Matthijs C. Brouwer
1, Frank Baas
2, Aeilko H. Zwinderman
3, Arie van der Ende
4,5,
Diederik van de Beek
1*
1Department of Neurology, Center of Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands,
2Department of Genome Analysis, Center of Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, The
Netherlands, 3Department of Biostatistics, Center of Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, The
Netherlands, 4Department of Medical Microbiology, Center of Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam,
Amsterdam, The Netherlands, 5Netherlands Reference Laboratory for Bacterial Meningitis, Center of Infection and Immunity Amsterdam (CINIMA), Academic Medical
Center, University of Amsterdam, Amsterdam, The Netherlands
Abstract
Recently, the biased b2-adrenoceptor/b-arrestin pathway was shown to play a pivotal role in crossing of the blood brain
barrier by Neisseria meningitidis. We hypothesized that genetic variation in the b2-adrenoceptor gene (ADRB2) may influence
susceptibility to bacterial meningitis. In a prospective genetic association study we genotyped 542 patients with CSF culture
proven community acquired bacterial meningitis and 376 matched controls for 2 functional single nucleotide
polymorphisms in the b2-adrenoceptor gene (ADRB2). Furthermore, we analyzed if the use of non-selective beta-blockers,
which bind to the b2-adrenoceptor, influenced the risk of bacterial meningitis. We identified a functional polymorphism in
ADRB2 (rs1042714) to be associated with an increased risk for bacterial meningitis (Odds ratio [OR] 1.35, 95% confidence
interval [CI] 1.04–1.76; p=0.026). The association remained significant after correction for age and was more prominent in
patients with pneumococcal meningitis (OR 1.52, 95% CI 1.12–2.07; p=0.007). For meningococcal meningitis the difference
in genotype frequencies between patients and controls was similar to that in pneumococcal meningitis, but this was not
statistically significant (OR 1.43, 95% CI 0.60–3.38; p=0.72). Patients with bacterial meningitis had a lower frequency of non-
selective beta-blockers use compared to the age matched population (0.9% vs. 1.8%), although this did not reach statistical
significance (OR 1.96 [95% CI 0.88–4.39]; p=0.09). In conclusion, we identified an association between a genetic variant in
the b2-adrenoceptor and increased susceptibility to bacterial meningitis. The potential benefit of pharmacological
treatment targeting the b2-adrenoceptor to prevent bacterial meningitis in the general population or patients with
bacteraemia should be further studied in both experimental studies and observational cohorts.
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Introduction
Community-acquired bacterial meningitis is a disease with high
mortality and morbidity, despite effective antimicrobial agents,
adjunctive dexamethasone and implementation of childhood
vaccination programmes [1–3]. Streptococcus pneumoniae and Neisseria
meningitidis are the leading causes of bacterial meningitis in adults,
with the first responsible for two thirds of cases in Europe and the
United States [1,4]. The disease is preceded by nasopharyngeal
colonization, which occurs in up to 100% of the normal
population for pneumococci and 18% for meningococci [5,6].
Following nasopharyngeal colonization some of the bacteria are
able to invade the bloodstream, avoid host defences and reach the
blood-brain barrier [7]. The mechanism by which the bacteria
cross the blood-brain barrier is not completely understood, but the
interaction between host cell receptors and the bacteria is thought
to contribute to transcytosis into the subarachnoid space [8].
Recently, Coureuil et al. showed an important role of the biased
b2-adrenoceptor/b-arrestin pathway in the pathophysiology of
meningococcal meningitis in vitro. The authors showed that N.
meningitidis is able to use the b2-adrenoceptor/b-arrestin signalling
pathway in endothelial cells to cross the blood-brain barrier [9].
The meningococcus was found to hijack the b2-adrenoceptor and
thereby stabilize its binding to the endothelium. Subsequently,
activation of the b-arrestin signalling pathway causes delocaliza-
tion of junctional proteins, resulting in gaps in the blood-brain
barrier through which the meningococcus invades the subarach-
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37618noid space. Previously, b-arrestin-1 was shown to participate in
receptor-mediated transcytosis of S. pneumoniae as well [10].
The human b2-adrenoceptor has several functional variants
determined by two single nucleotide polymorphisms (SNPs),
rs1042713 and rs1042714 in the ADRB2 gene [11]. Although
the genetic variant of the receptor displayed normal agonist
binding and functional coupling in a functional study, a markedly
altered degree of agonist-promoted down regulation of receptor
expression was shown [11]. Both SNPs have been associated with
several diseases, such as asthma [12,13]. Familial aggregation and
genetic association studies have suggested a genetic influence on
susceptibility to pneumococcal and meningococcal infections [14].
SNPs have also been suggested to influence the phenotype of
disease, i.e. the development of meningitis or sepsis [15]. We
hypothesized that crossing of the blood-brain barrier by microor-
ganisms such as N. meningitidis and S. pneumoniae, the two most
common causative bacteria of meningitis, may be influenced by
these ADRB2 SNPs. We further analysed if the use of beta-blockers
influenced the risk of acquiring bacterial meningitis, as non-
selective beta-blockers may limit the availability of b2-adrenocep-
tors for bacteria to cross the blood-brain barrier.
Methods
We performed a prospective nationwide genetic association
study on the influence of ADRB2 SNP rs1042713 and rs1042714
on susceptibility to bacterial meningitis. In this study we included
bacterial meningitis patients older than 16 years of age with
positive cerebrospinal fluid (CSF) cultures who were identified by
The Netherlands Reference Laboratory for Bacterial Meningitis
(NRLBM) from March 2006 to June 2010 [3]. The NRLBM
receives bacterial isolates from approximately 85% of bacterial
meningitis patients in the Netherlands and provided the names of
the hospitals where patients with bacterial meningitis had been
admitted 2–6 days previously. The treating physician was
contacted, and written informed consent was obtained from all
participating patients or their legally authorized representatives.
Patients could also be included by physicians familiar with the
study through a 24/7 telephone service. Patients with hospital-
acquired bacterial meningitis and negative CSF cultures were
excluded. Controls for exposure/susceptibility were patients’
partners or their non-related proxies living in the same dwelling,
as household members are exposed to similar bacteria [16].
Furthermore, this choice of controls guaranteed similar socio-
economic background of patients and controls. Data on age, sex
and ethnicity of patients and controls were collected. For patients,
information on medication use on admission was recorded. Use of
beta-blockers was categorized in selective and non-selective beta-
blockers. We compared the use of selective (b1) beta-blockers and
non-selective (b1 and b2) blockers of bacterial meningitis patients
with that of the age corrected general population.
Blood from patients and controls for DNA extraction was
collected in sodium/EDTA tubes. DNA was isolated with the
Gentra Puregene isolation kit (Qiagen, Hilden, Germany) and
quality control procedures were performed to determine the yield
of isolation. The rs1042713 and rs1042714 SNP were genotyped
using TaqMan SNP Genotyping Assays (Applied Biosystems,
Foster City, California, USA) in a LightCycler480 (Roche, Basel,
Switzerland) using the Fast Start Universal Probe Mix (Roche) for
rs1042713 and TaqMan Genotyping Master Mix (Applied
Biosystems) for rs1042714, by the Genetics Core Facility in the
Academic Medical Center, Amsterdam, the Netherlands. Labo-
ratory personnel were blinded to clinical information. The Mann-
Whitney U test was used to identify differences in baseline
characteristics between groups with respect to continuous
variables, and dichotomous variables were compared with use of
the x
2 test. These statistical tests were 2-tailed, and a p-value of
,0.05 was regarded as significant. Differences in genotype
frequencies were analyzed with the x
2 or Fishers’ exact tests by
use of PASW18. Logistic regression analysis was used to analyse
the difference in genotype frequency between patient and controls
corrected for age. Subgroup analyses were performed for
pneumococcal and for meningococcal meningitis patients. Fur-
thermore, we separately compared the genotype frequency of
bacterial meningitis patients with and without otitis media and/or
sinusitis to controls. Since the ADRB2 SNPs are thought to
influence the blood-brain barrier crossing of bacteria, a potential
effect is expected to be absent in patients with meningitis due to
continuous infection from otitis media and/or sinusitis.
We calculated whether the genotype frequencies in white
controls concurred with the Hardy Weinberg equilibrium (HWE)
by use of a x
2 test with one degree of freedom with a p,0.001 to
indicate significance. The study was approved by the research
ethics committee of the Academic Medical Centre, Amsterdam,
The Netherlands.
Results
From March 2006 to June 2010, 734 patients with culture
proven bacterial meningitis were included: in 534 (73%) cases S.
pneumoniae was the causative organism, in 91 (12%) N. meningitidis
and 109 (15%) were due to other microorganisms. DNA was
available for 542 (74%) patients and 376 controls. The mean age
of included patients was 55 years and 49.6% of the patients were
male. Sex, age, ethnicity and socio-economic background were
similar between patients and controls (Table 1). Clinical charac-
teristics of the patient population are presented in Table 2.
Genotyping was successful in 99.3% of the samples and the
genotype frequency of controls for both SNPs concurred with the
Hardy-Weinberg Equilibrium. Genotype frequencies were similar
between patients of different ethnic background. The Gln/Glu
genotype of the rs1042714 was associated with increased
susceptibility to bacterial meningitis (Table 3). The genotype was
found in 271 of 542 (50%) patients and 160 of 376 (42%) controls
(odds ratio [OR] 1.35, 95% confidence interval [CI] 1.04–1.76;
p=0.026). After correction for age, rs1042714 was still signifi-
cantly associated with susceptibility (OR 1.37, 95% CI 1.05–1.79;
p=0.023). The results were similar when the analysis was limited
to white patients and controls (OR 1.36, 95% CI 1.04–1.79;
p=0.033). The genotype distribution of rs1042713 was similar
between patients and controls. Subgroup analysis showed that the
Gln/Glu genotype was found in 200 of 396 (51%) pneumococcal
meningitis patients compared to 116 of 289 (40%) controls (OR
Table 1. Age, sex and ethnicity of 542 patients and 376
controls.
Characteristic Patients Controls
Age 54.7 (617) 55.7 (615)
Male sex 269 (49.6%) 187 (49.7%)
Ethnicity
White 510 (94%) 361 (96%)
African 24 (4.4%) 13 (3.5)
Asian 8 (1.5) 2 (0.5%)
doi:10.1371/journal.pone.0037618.t001
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the risk genotype showed a similar distribution. It was found in 36
of 69 (52%) patients and 13 of 30 (43%) controls, but this did not
reach statistical significance due to the low numbers of patients
(OR 1.43, 95% CI 0.60–3.38; p=0.72). In the subgroup analysis
of patients with otitis media and/or sinusitis, there was no
association of rs1072714 and susceptibility (p=0.15), while in
patients without otitis media and/or sinusitis the rs1072714
genotype was still associated with increased susceptibility (OR
1.38, 95% CI 1.03–1.85; p=0.030). Our study, however, lacked
power to meet the standard of demonstrating a statistically
significant interaction of otitis media and sinusitis by genotype.
Both ADRB2 SNPs were not associated the rate of unfavourable
outcome or mortality rate.
Non-selective beta-blockers may present a means of preventing
bacterial meningitis by blocking the b2-adrenoceptor, and are
used by a substantial part of the population for hypertension and
chronic heart failure [17]. A total of 104 of 642 patients (16%) for
whom medication was specified used beta-blockers, of which 6
(0.9%) used non-selective beta-blockers and 98 (15%) b1-selective
beta-blockers (Table 4). Predisposing factors for bacterial menin-
gitis were present in all 6 patients using non-selective beta-
blockers, 56 (57%) patients using selective beta-blockers and 278
(52%) of patients using no beta-blockers (p=0.041). Four of the
patients on non-selective beta-blockers presented with otitis media
Table 2. Clinical characteristics 542 patients with bacterial
meningitis on admission and outcome.
Characteristics No./no. of patients
a
Mean age, yr (range) 55 (17–93)
Male/female sex – no. 269/273
Duration of symptoms ,24 hours 233/520 (45)
Predisposing conditions
Otitis media/sinusitis 192/542 (35)
Pneumonia 49/535 (9)
Immunocompromised state
b 121/530 (23)
Symptoms on presentation
Headache 413/535 (77)
Nausea 290/535 (54)
Neck stiffness 400/535 (75)
Temperature $38uC 408/535 (76)
Signs of septic shock
c 270/525 (51)
Score on Glascow Coma Scale
d 11 (9–14)
Altered mental status (Glascow Coma Scale ,14) 385/531 (73)
Coma (Glascow Coma Scale ,8 ) 69/531 (13)
Outcome
Unfavourable
f 126/514 (23)
Death 36/514 (7)
aData are number/number evaluated (%), and median (interquartile range)
unless otherwise stated.
bImmunocompromised was defined as the use of immunosuppressive drugs,
the presence of diabetes mellitus or alcoholism, and patients with the human
immunodeficiency virus (HIV).
cDefined as a systolic blood pressure #90 mmHg, a diastolic blood pressure
,60 mmHg and/or heart rate $120/min.
dUnfavourable outcome was defined as a Glascow Outcome Score (GOS) ,5, a
score of 1 indicates death, 2 indicates vegetative state, 3 indicates severe
disability, 4 indicates moderate disability and 5 indicates mild or no disability.
doi:10.1371/journal.pone.0037618.t002
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immunocompromised. Data on beta-blocker use in the control
population was not available to assess if non-selective beta-blocker
use decreased the risk of bacterial meningitis. Data from the
national pharmaceutical registry (Foundation of Pharmaceutical
Statistics) showed 12.9% of the age corrected general population
use b1-selective beta-blockers and 1.8% non-selective beta-
blockers [17]. A statistical trend toward lower use of non-selective
beta-blockers and higher use of selective beta-blockers was
observed in the meningitis cohort compared to the general
population corrected for age (non-selective beta-blockers 0.9 vs.
1.8%; OR 1.96 [95% CI 0.88–4.39]; p=0.09; selective beta-
blockers 15.2% vs. 12.9%, OR 0.83 [95% CI 0.67–1.02], p=0.08)
[18].
Discussion
In a nationwide prospective genetic association study, we show
an association of genetic variation in G protein-coupled receptors
with susceptibility to bacterial meningitis [14]. The effect of
ADRB2 SNP rs1042714 was most clear for pneumococcal
meningitis. We did not identify an association of rs1042714 with
susceptibility to meningococcal meningitis and matched controls,
although the difference in genotype frequencies between patients
and controls was similar to that seen in pneumococcal meningitis.
Further studies are needed to validate the identified associations in
bacterial meningitis and pneumococcal meningitis, and determine
the role of rs1042714 in a larger population of meningococcal
meningitis patients. Furthermore, it would be interesting to
compare meningitis patients with those that had bacteraemia
due to the same pathogens, who did not develop meningitis.
The importance of G protein-coupled receptors for microor-
ganisms to cross the blood-brain-barrier has been described in vitro
in the binding of S. pneumoniae to the platelet activating factor
receptor (PAFr), which facilitates transcytosis [8]. PAFr knockout
mice showed to be protected against pneumococcal meningitis
after intravenous injection of pneumococci [10]. Binding of S.
pneumoniae to the b2-adrenoceptor has not been studied so far. The
described molecular mechanisms of the interaction of S. pneumoniae
and PAFr, and that of N. meningitidis and the b2-adrenoceptor are
quite different, but in both processes b-arrestin-1 plays a crucial
role [9]. The identified association between the ADRB2 SNP and
susceptibility to pneumococcal meningitis in our study suggests this
receptor may be of similar importance for the pathophysiology of
pneumococcal meningitis as was recently shown for meningococ-
cal meningitis. As no interaction between the b2-adrenoceptor and
the pneumococcus has been shown, our results must be interpreted
with caution and regarded as explorative. It is likely that micro-
organisms need multiple receptors to achieve sufficient adhesion to
the endothelial cells and cross the blood-brain barrier [9]. Further
experimental data are needed to determine the interaction of S.
pneumoniae with the b2-adrenoceptor.
In this study we identified the b2-adrenoceptor as a potential
target for therapy to prevent bacteria crossing the blood-brain
barrier. The availability of the b2-adrenoceptor can be pharma-
cologically decreased by either binding of antagonists (beta-
blockers) or downregulation of the receptor following catechol-
amine treatment [19]. It has been suggested that patients treated
with catecholamines for meningococcal septic shock may benefit
from downregulation of the receptor, as this will interfere with
crossing of the blood brain barrier by the pathogen [19].
Prevention of bacterial invasion of the central nervous system
(CNS) in sepsis patients is likely to reduce neurologic complications
and improve outcome. The yield of this treatment strategy is
probably limited, as concomitant initiation of antimicrobial
treatment reduces the need for prevention of bacterial spread to
the CNS. However, cases due to multiresistant bacteria may
benefit from this approach.
Patients using non-selective beta-blockers were underrepresent-
ed in our patient cohort, while patients using selective beta-
blockers were overrepresented, although this difference was not
statistically significant. The additional blocking of b2-adrenoceptor
by non-selective beta-blockers compared to selective beta-blockers
may prevent bacteria crossing the blood-brain barrier and explain
that patients on non-selective beta-blockers only developed
meningitis when predisposing conditions such as otitis media or
immunocompromised state were present. The association of beta-
blockers with susceptibility to bacterial meningitis is however
difficult to determine, since we have no data on the use of beta-
blockers in the matched control population. Furthermore, an
interaction between beta-blocker efficacy and rs1042714 has been
reported that hinders a straightforward analysis [20]. The
potential benefit of pharmacological treatment targeting the b2-
adrenoceptor to prevent bacterial meningitis in patients with
bacteraemia should be further studied in both experimental studies
and observational case-control studies.
Our study has several limitations. First, the numbers of patients
included in our study is relatively small for a study of
polymorphisms. However, this is the largest genetic association
study so far in bacterial meningitis patients, and provides
interesting leads for further clinical and experimental studies.
Furthermore, we did not replicate our findings in other case-
control studies of adults with bacterial meningitis. Currently, no
such studies are at our disposal to validate our findings. Third, we
did not have information on the medical history of the control
population and were therefore unable to correct for diseases that
may result in confounding. Finally, in this study we show an
association between rs1042714 and susceptibility but do functional
Table 4. Use of beta-blockers in study bacterial meningitis patients, the general Dutch population and age corrected general
population.
Characteristic
Patients
N=638
General population
a
N=16.575.000 Age corrected population
b
Beta-blockers 103 (16%) 1.445.000 (8.7%) 2.480.000 (15.0%)
Non-selective 6 (0.8%) 191.000 (1.2%) 304.000 (1.8%)
Selective 97 (15.2%) 1.233.000 (7.4%) 2.140.000 (12.9%)
No beta-blockers 535 (84%) 15.130.000 (91.2%) 14.096.000 (85.0%)
aNumbers do not add up to 100% as not all beta-blockers could be specified. Source: Foundation for Pharmaceutical Statistics [17]. Source: Statistics Netherlands [18].
doi:10.1371/journal.pone.0037618.t004
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must be interpreted with caution.
In conclusion, we identified an association between rs1042714
ADRB2 and susceptibility to bacterial meningitis. We have linked
the b2-adrenoceptor/b-arrestin pathway with increased suscepti-
bility to bacterial meningitis in vivo.
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